Glycopyrronium Bromide 0.5mg/mL and Neostigmine Metilsulfate 2.5mg/mL Injection

País: Nova Zelanda

Idioma: anglès

Font: Medsafe (Medicines Safety Authority)

ingredients actius:

Glycopyrronium bromide 0.5 mg/mL; Neostigmine metilsulfate 2.5 mg/mL

Disponible des:

Max Health Limited

Designació comuna internacional (DCI):

Glycopyrronium bromide 0.5 mg/mL

formulario farmacéutico:

Solution for injection

Composición:

Active: Glycopyrronium bromide 0.5 mg/mL Neostigmine metilsulfate 2.5 mg/mL Excipient: Citric acid Citric acid monohydrate Dibasic sodium phosphate dodecahydrate Sodium hydroxide Water for injection

Unidades en paquete:

Ampoule, glass, 10 x 1mL, type I vials, 10 dose units

clase:

Prescription

tipo de receta:

Prescription

Fabricat per:

Harman Finochem Limited

indicaciones terapéuticas:

Reversal of residual non-depolarising (competitive) Neuromuscular block.

Resumen del producto:

Package - Contents - Shelf Life: Ampoule, glass, type I, 10 x 1mL - 10 dose units - 12 months from date of manufacture stored at or below 25°C protect from light

Data d'autorització:

2012-07-25

Fitxa tècnica

NEW ZEALAND DATA SHEET
Page 1 of 6
1
PRODUCT NAME
Glycopyrronium Bromide 0.5 mg/mL and Neostigmine Metilsulphate 2.5
mg/mL Solution for
Injection
2
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each 1ml of solution contains Glycopyrronium Bromide (Glycopyrrolate)
0.5 mg and Neostigmine
Metilsulfate 2.5 mg.
Excipient with known effect:
This medicine contains less than 1 mmol sodium (23 mg) per 1ml,
essentially ‘sodium free’.
For the full list of excipients, see section 6.1.
3
PHARMACEUTICAL FORM
A clear and colourless sterile solution for Injection.
4
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Reversal of residual non-depolarising (competitive) Neuromuscular
block.
4.2
DOSE AND METHOD OF ADMINISTRATION
For intravenous injection.
Adults and elderly patients
1-2ml intravenously over a period of 10 to 30 seconds (equivalent to
Neostigmine Metilsulfate 2.5 mg
with Glycopyrronium Bromide 0.5 mg to Neostigmine Metilsulfate 5 mg
with Glycopyrronium
Bromide 1 mg). Alternatively, 0.02 ml/kg intravenously over a period
of 10 to 30 seconds may be used,
(equivalent to Neostigmine Metilsulfate 0.05 mg/kg with Glycopyrronium
Bromide 0.01 mg/kg), dose
may be repeated (total maximum 2 ml).
Paediatric0.02 ml/kg intravenously over a period of 10 to 30 seconds
(equivalent to Neostigmine
Metilsulfate 0.05 mg/kg with Glycopyrronium Bromide 0.01 mg/kg).
These doses may be repeated if adequate reversal of neuromuscular
blockade is not achieved. Total
doses in excess of 2 ml are not recommended as this dose of
Neostigmine may produce depolarising
neuromuscular block.
4.3
CONTRAINDICATIONS
Hypersensitivity to the active substance or to any of the excipients
listed in section 6.1.
Glycopyrronium Bromide and Neostigmine Metilsulfate Injection should
not be given to patients with
known hypersensitivity to either of the two active ingredients or
given to patients with mechanical
obstruction of the gastrointestinal or urinary tracts. In addition,
this product should not be given in
conjunction with suxamethonium, as Neostigmine potentiate